{
 "ticker": "IBRN",
 "name": "iShares Neuroscience and Healthcare ETF",
 "issuer": "iShares",
 "desk": "themes",
 "url": "https://etfiq.com/funds/IBRN",
 "html": "https://etfiq.com/funds/IBRN",
 "markdown": "https://etfiq.com/funds/IBRN.md",
 "as_of": "2026-09-11",
 "verdict": "IBRN holds 73 stocks, and 96% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "4.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBRN, already in the S&P 500: 4.3%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "100.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBRN, active share vs the S&P 500: 100.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "45.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBRN, top ten holdings: 45.7%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+45.9%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBRN, total return, 1 year: +45.9%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$5m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "IBRN, net assets: $5m (SEC filing, whole fund, as filed for Apr 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.47%",
   "source": "485BPOS XBRL, Nov 21, 2025",
   "as_of": "2026-09-11",
   "sentence": "IBRN, expense ratio: 0.47% (485BPOS XBRL, Nov 21, 2025)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Therapeutics and medical devices",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Aug 26, 2022",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "4.3%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "100.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "0.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "100.0%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "45.7%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "73",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 10, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "PRAXIS PRECISION MEDICINES 5.2%, DIANTHUS THERAPEUTICS INC 5.0%, SCHOLAR ROCK HOLDING 4.9%, ACADIA PHARMACEUTICALS 4.9%, XENON PHARMACEUTICALS 4.5%, ARROWHEAD PHARMACEUTICALS 4.5%, ARGENX SE ADR 4.3%, BIOGEN 4.3%, ALKERMES 4.2%, NEUROCRINE BIOSCIENCES 3.8%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$5m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22128.0%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.47%",
   "source": "485BPOS XBRL, Nov 21, 2025"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.47%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "FBT 18%, PBE 15%, PSIL 12%, IBBQ 11%, BBP 11%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+7.4%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+4.1 pts",
   "Gap to Nasdaq-100": "+8.2 pts"
  },
  {
   "window": "6 months",
   "Total return": "+20.7%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+4.7 pts",
   "Gap to Nasdaq-100": "0.0 pts"
  },
  {
   "window": "1 year",
   "Total return": "+45.9%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+28.4 pts",
   "Gap to Nasdaq-100": "+22.9 pts"
  },
  {
   "window": "3 years",
   "Total return": "+66.3%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221211.6 pts",
   "Gap to Nasdaq-100": "\u221228.8 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+54.5%",
   "S&P 500": "+99.0%",
   "Gap to S&P 500": "\u221244.4 pts",
   "Gap to Nasdaq-100": "\u221283.7 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of IBRN is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 10, 2026, 4% of IBRN by weight is stocks the S&P 500 already holds. Its active share against the index is 100%, so that share is the part doing something different."
  },
  {
   "q": "What does IBRN hold?",
   "a": "73 positions as published by its issuer for Sep 10, 2026, with the top ten at 46% of the fund. The largest are PRAXIS PRECISION MEDICINES at 5.2%, DIANTHUS THERAPEUTICS INC at 5.0%, SCHOLAR ROCK HOLDING at 4.9%."
  },
  {
   "q": "Has IBRN beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 IBRN returned +45.9% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 28.4 points."
  },
  {
   "q": "What does IBRN cost?",
   "a": "The prospectus expense ratio is 0.47% a year. Because 100% of the fund differs from the S&P 500, the fee on that differing part works out at 0.47%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}